晚期阴茎癌治疗的研究现状和进展  

Research status and progress in therapy of advanced penile cancer

作　　者：冯紫丹 吕沛萱 胡希恒[2] FENG Zidan;LYU Peixuan;HU Xiheng(Xiangya School of Medicine,Central South University,Changsha,Hunan 410028,China;Department of Urology,Xiangya Hospital,Central South University,Changsha,Hunan 410008,China)

机构地区：[1]中南大学湘雅医学院,湖南长沙410028 [2]中南大学湘雅医院泌尿外科,湖南长沙410008

出　　处：《中国医学工程》2022年第7期60-64,共5页China Medical Engineering

摘　　要：阴茎癌是一种罕见的泌尿生殖系统肿瘤。Ⅲ、Ⅳ期阴茎癌的治疗效果及预后较差。单纯手术治疗对晚期阴茎癌患者疗效有限,放疗可作为无法手术以及术后复发患者的姑息性治疗。手术联合化疗对晚期阴茎癌患者疗效较好,目前一线化疗方案为顺铂+紫杉醇+异环磷酰胺(TIP)。表皮生长因子受体(EGFR)相关靶向药物已被用做二线治疗,免疫检查点抑制剂(ICI)的临床试验也显示出免疫治疗在晚期阴茎癌中的应用前景。多模式治疗(MMT)具有探索的潜力,已逐渐成为晚期阴茎癌治疗的首选方式,有望改写晚期阴茎癌的治疗方法。期待未来有更大样本的前瞻性研究和更多高质量循证医学的临床试验数据,为晚期阴茎癌患者的治疗带来更多希望。Penile cancer is a rare cancer.The therapeutic efficacy and prognosis of stage III and IV penile cancer are not satisfactory.Surgical treatment alone has limited effect on patients with advanced penile cancer.Radiotherapy is a palliative treatment for those who are inoperable or have postoperative recurrence.Surgery combined with chemotherapy has a good effect on late staged patients.And TIP is the current first-line chemotherapy regimen.EGFR-targeted therapy has been received as second-line therapy.Clinical trials of immune checkpoint inhibitors have shown that immunotherapy is promising in advanced penile cancer.Multimodal treatment has gradually become the preferred treatment for advanced patients,which is expected to rewrite the standard treatment strategy for advanced penile cancer.In the future,multi-institutional studies,larger prospective clinical research and more high-quality trials data are urgently needed to advance the treatment for patients with advanced penile cancer.

关 键 词：阴茎癌 免疫检查点抑制剂 靶向治疗 多模式治疗 

分 类 号：R737.27[医药卫生—肿瘤]